Literature DB >> 18568764

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Vera J Suman1, Amylou Dueck, Daniel J Sargent.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18568764     DOI: 10.1080/07357900801971057

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  5 in total

1.  Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Jungnam Joo; Nancy L Geller; Benjamin French; Stephen E Kimmel; Yves Rosenberg; Jonas H Ellenberg
Journal:  Clin Trials       Date:  2010-08-06       Impact factor: 2.486

2.  Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Authors:  Robert E Martell; David Sermer; Kenneth Getz; Kenneth I Kaitin
Journal:  Oncologist       Date:  2012-12-20

3.  Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.

Authors:  Cornelia Schuster; Hans P Eikesdal; Hanne Puntervoll; Jürgen Geisler; Stephanie Geisler; Daniel Heinrich; Anders Molven; Per E Lønning; Lars A Akslen; Oddbjørn Straume
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

4.  First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.

Authors:  Andrea Molckovsky; Lillian L Siu
Journal:  J Hematol Oncol       Date:  2008-10-29       Impact factor: 17.388

5.  Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.

Authors:  Monia Ezzalfani; Sarah Zohar; Rui Qin; Sumithra J Mandrekar; Marie-Cécile Le Deley
Journal:  Stat Med       Date:  2013-01-21       Impact factor: 2.373

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.